Evidence map›Paper›PMID 41305536›Full record

ArticleViruses2025

Network Dynamics and Evolutionary Drivers of HIV Drug Resistance in Eastern China, from 2022 to 2024.

Dongqing Cao, Hui Xing, Yi Feng, Jiafeng Zhang, Liangkang Zhou, Zhuojing Jiang, Jinkun Chen, Tingting He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dongqing CaoShaoxing Center for Disease Control and Prevention, Shaoxing 312000, China.
Hui XingState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Yi FengState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Jiafeng ZhangDepartment of HIV/AIDS and STDs Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.ORCID 0000-0003-4288-5516
Liangkang ZhouShaoxing Center for Disease Control and Prevention, Shaoxing 312000, China.
Zhuojing JiangShaoxing Center for Disease Control and Prevention, Shaoxing 312000, China.
Jinkun ChenShaoxing Center for Disease Control and Prevention, Shaoxing 312000, China.
Tingting HeShaoxing Center for Disease Control and Prevention, Shaoxing 312000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of HIV drug resistance poses a significant challenge. This study aimed to investigate the epidemiological dynamics and molecular characteristics of pretreatment drug resistance (PDR) and acquired drug resistance in Shaoxing, Eastern China.

methodsFrom 2022 to 2024, 571 newly diagnosed HIV-infected individuals and 119 individuals with antiretroviral treatment failure were enrolled. Molecular transmission networks and Bayesian analysis were employed to identify key drug-resistant clusters and trace their origins.

resultsThe overall PDR prevalence was 14.4% (85/571). PDR to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was 9.8% (56/571), significantly higher than to NRTIs (1.1%, 6/571) and PIs (3.7%, 21/571) (

conclusionTargeted interventions against specific subtypes and transmission clusters, alongside continuous resistance surveillance, are essential to curb the spread of drug-resistant HIV and optimize ART regimens.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsAdultBayes TheoremChinaEvolution, MolecularFemaleGenotypeHumansMaleMiddle AgedMutationPhylogenyPrevalenceAnti-HIV Agentsacquired drug resistancedrug mutationHIV/AIDSmolecular epidemiologypretreatment HIV-drug resistancetransmission networks

Identifiers

PMID41305536
PMCPMC12656853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.